Featured Reports, News & Insights.
ICER Uses Observational Real-World Evidence to Update 2018 Assessment on Therapies for Hereditary Angioedema, Finds Therapies Far Less Cost-Effective Than Earlier Estimates
Patients initiating therapy in real-world dataset had less frequent baseline attack rates than rates from clinical trials used in 2018 assessment; as a result, all three therapies are far less cost-effective than earlier estimates and would require a price discount of at least 50% to reach common thresholds of cost-effectiveness.
08/24/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020In Landmark International Program, HTA Agencies Around the World Access ICER’s Customizable COVID-19 Cost-Effectiveness Model
Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform Ministerial recommendations on remdesivir; other HTA agencies and research groups in the United Kingdom, Australia, Canada and South Africa plan to access the model.
10/09/2020